Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia

Gangat, Naseema; Bleeker, Jonathan; Lynch, Douglas; Olteanu, Horatiu; Letendre, Louis; Tefferi, Ayalew

doi:10.3324/haematol.2022.281398

Cited by 13 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11 Daratumumab demonstrated rapid and sustained response in treatment-refractory acquired idiopathic PRCA in a 74-year-old patient. 12 Daratumumab also successfully managed a patient of post-transplant PRCA with responses observed within 3 weeks. 13 Rituximab successfully managed two patients with PRCA secondary to CLL, and the patients became transfusion independent.…”

Section: Discussionmentioning

confidence: 97%

Idiopathic pure red cell aplasia: A case series from India

Mahajan,

Goel,

Patel

et al. 2023

Asian J Med Sci

View full text Add to dashboard Cite

Pure red cell aplasia (PRCA) is a rare hematologic disorder characterized by normocytic normochromic anemia with reticulocytopenia and depleted erythroid precursors. It is reported mainly from western countries. We report our experience in two patients of PRCA from India, the clinical characteristics, differential diagnosis, and their management. Our patients showed improvements following treatment with corticosteroids, blood transfusion, and/or rituximab.

show abstract

Section: Discussionmentioning

confidence: 97%

Idiopathic pure red cell aplasia: A case series from India

Mahajan,

Goel,

Patel

et al. 2023

Asian J Med Sci

View full text Add to dashboard Cite

show abstract

“…In as many as 75% of CCS cases, the cytogenetic analysis revealed the reciprocal translocation t(12;22)(q13;q12) involving the EWSR1 gene and the ATF1 gene. 15,16 Four types of EWSR1/ ATF1 chimeric transcripts have been noted in CCS. 1,17 This translocation has not been described in malignant melanoma and, therefore, can help distinguish between the 2 diagnoses.…”

Section: Discussionmentioning

confidence: 99%

“…Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum [see References (15)…”

Section: Interference With Serological Testingmentioning

confidence: 99%

Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman

2023

Oncology

View full text Add to dashboard Cite

BACKGROUND Clear cell sarcoma (CCS) is a rare but aggressive malignancy that typically occurs in young adults and is characterized by soft tissue tumors of the extremities. CCS can be difficult to distinguish from metastatic melanoma based solely on histology and immunohistochemistry (IHC) because of the significant overlap between them. However, it is imperative to get an accurate clinical diagnosis, as it informs disease staging and treatment options for patient care. Present in approximately 75% of CCS cases, the EWSR1 gene rearrangement detected by fluorescence in situ hybridization (FISH) can help with establishing a diagnosis; the underlying reciprocal translocation has never been reported in cutaneous melanoma. CASE DESCRIPTION We reviewed a case of a young woman who presented with a confusing picture of widespread lymphadenopathy, cutaneous metastases, and electrolyte derangements and was subsequently diagnosed with metastatic CCS. CONCLUSIONS This case suggests possible value in performing molecular testing when a clinical picture does not correspond with what is expected for melanoma. It also raises the question of whether CCS cases may be underreported. This case highlights an uncommon presentation that may not be recognized as a manifestation of CCS by an oncologist who is not a sarcoma specialist. It is unclear how COVID-19 vaccination contributed to her clinical presentation, and it is also unclear whether an early diagnosis would have changed her clinical outcome.

show abstract

“…З А К Л Ю Ч Е Н И Е Полученные данные, а также отдельные публи кации по данному вопросу дают основание судить о потенциальной безопасности и эф ф екти в ности даратумумаба в качестве терапии ПККА как у взрослых реципиентов ТГСК, так и у детей [2][3][4][5][14][15][16][17][18]. Предположения о механизме патоге неза ПККА у данной группы пациентов дают осно вания рассматривать возможность применения 112 КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ даратумумаба в первой линии терапии, что, безус ловно, заслуживает более предметного анализа [3,12].…”

Section: периферическая кровьunclassified

“…Возможные механизмы клеточного лизиса включают комплемент-и антителозависимую клеточно-опосре дованную цитотоксичность [16]. В профильных высо корейтинговых изданиях все чаще можно встретить описания клинических случаев эффективного приме нения даратумумаба в лечении ПККА у больных после ТГСК [2][3][4][5][15][16][17][18].…”

unclassified

Daratumumab in the treatment of pure red cell aplasia after pediatric allogeneic stem cell transplantation

Arakelyan

Blagov

Kovrygin

et al. 2023

Voprosy gematologii/onkologii i immunopatologii v pediatrii

View full text Add to dashboard Cite

Pure red cell aplasia (PRCA) is a rare complication of AB0-incompatible allogeneic hematopoietic stem cell transplantation, which manifests as a partial or complete absence of erythroid lineage in recipients with normal function of other hematopoietic lineages. There is a hypothesis, that lysis of erythroid precursors occurs because of antibody formation by population of residual B-lymphocytes and/or long-lived recipient’s plasma cells, which are capable for proliferation and active expression of the CD38 marker. That is why the invention of the IgG1 monoclonal antibody to CD38 presented as a new potentially effective targeted therapeutic option for patients with refractory PPCA. The article summarize clinical data on daratumumab for the therapy of PRCA in pediatric allogeneic hematopoietic stem cell transplantation recipients. The patients' parents gave their consent to the use of their children's data, including photographs, for research purposes and in publications.

show abstract

Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia

Cited by 13 publications

References 9 publications

Idiopathic pure red cell aplasia: A case series from India

Idiopathic pure red cell aplasia: A case series from India

Unusual Clinical Presentation of Clear Cell Sarcoma in a Young Woman

Daratumumab in the treatment of pure red cell aplasia after pediatric allogeneic stem cell transplantation

Contact Info

Product

Resources

About